当代机械循环支持时代心脏再移植桥接的结局
机械循环支持组30天死亡率显著更高(17.8% vs 4.8%,P<.01),但使用心室辅助装置或全人工心脏桥接者中期结局与非机械循环支持组相当。体外膜氧合桥接再移植仍为相对禁忌。
要点
- 机械循环支持桥接再移植属高风险人群,30天死亡率17.8% vs 4.8%。
- 心室辅助装置或全人工心脏桥接者中期结局与非机械循环支持组相当。
- 体外膜氧合桥接再移植仍为相对禁忌。
核心结论
- 需要机械循环支持桥接再移植的患者属于高风险队列。
- 当病情允许使用心室辅助装置或全人工心脏桥接时,中期结局与非机械循环支持队列相当。
- 体外膜氧合桥接再移植仍为相对禁忌证。
研究设计与样本
- 比较机械循环支持桥接组(n=81)与非机械循环支持组(n=383)的移植前后数据。
主要发现
- 机械循环支持组平均年龄41.2±16岁,非机械循环支持组42.1±15.7岁(P=.64)。
- 机械循环支持组中体外膜氧合29例(35.8%)、全人工心脏13例(16.0%)、临时或持久心室辅助装置39例(48.1%)。
- 机械循环支持组39%因原发性移植物功能障碍或急性排斥被列入名单,非机械循环支持组为6%(P<.01)。
- 机械循环支持组30%因心脏移植物血管病变被列入名单,非机械循环支持组为59%(P<.01)。
临床怎么用
- 对再移植候选者,优先考虑心室辅助装置或全人工心脏作为桥接策略。
- 体外膜氧合桥接再移植应视为相对禁忌,需谨慎评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcomes have improved in patients bridged to heart transplant on contemporary continuous-flow ventricular assist devices over the past decade. We evaluated mechanical circulatory support as a means to bridge patients to cardiac retransplantation. METHODS: We retrospectively reviewed 464 patients who underwent cardiac retransplant from the United Network for Organ Sharing database between January 2006 and November 2016. Pre- and post-transplant data were compared between patients bridged to retransplant with mechanical circulatory support (n = 81) and those without mechanical circulatory support (n = 383). RESULTS: The mean ages for the patients in the mechanical circulatory support and nonmechanical circulatory support cohorts were 41.2 ± 16 years and 42.1 ± 15.7 years, respectively (P = .64). Patients bridged with mechanical circulatory support were placed on extracorporeal membrane oxygenation (n = 29, 35.8%), a total artificial heart (n = 13, 16.0%), or a temporary or durable ventricular assist device (n = 39, 48.1%). Twelve patients (14.8%) were placed on a second device before retransplant. Thirty-nine percent of the mechanical circulatory support group were indicated for listing because of primary graft dysfunction or acute rejection versus 6% of the nonmechanical circulatory support group (P < .01). Likewise, 30% of patients in the mechanical circulatory support group were listed for cardiac allograft vasculopathy compared with 59% of the nonmechanical circulatory support group (P < .01). Thirty-day mortality was significantly higher in the mechanical circulatory support group (17.8% vs 4.8%, P < .01). However, patients who were bridged with a ventricular assist device or total artificial heart had comparable midterm outcomes to the nonmechanical circulatory support group. CONCLUSIONS: Patients who require mechanical circulatory support bridge to retransplantation belong to a high-risk cohort. Comparable midterm outcomes to the nonmechanical circulatory support cohort were demonstrated when patients' conditions allow for bridge with a ventricular assist device or total artificial heart. Bridging to retransplantation with extracorporeal membrane oxygenation remains a relative contraindication.
引用
- Sanchez JE, Takayama H, Ando M, et al. Outcomes of bridge to cardiac retransplantation in the contemporary mechanical circulatory support era. J Thorac Cardiovasc Surg. 2019. PMID: 31097199. doi:10.1016/j.jtcvs.2019.01.135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。